Thee S, Detjen A, Wahn U, Magdorf K
Department of Paediatric Pneumology and Immunology, Helios Klinikum Emil von Behring, Chest Hospital Heckeshorn, Berlin, Germany.
Int J Tuberc Lung Dis. 2009 Sep;13(9):1106-11.
Rifampicin (RMP) is an essential drug in paediatric anti-tuberculosis treatment. The current World Health Organization (WHO) guidelines recommend an oral dosage of 10 (8-12) mg per kg body weight.
To present a study investigating RMP serum levels in children after oral medication of RMP alone and after combination treatment with ethambutol (EMB).
RMP serum levels in children of different age groups were determined after a single oral administration of 10 mg/kg RMP alone as well as after combination with 35 mg/kg EMB.
RMP serum levels were lower than those expected in adults receiving a similar oral dose. RMP serum levels in combination treatment were even lower than in monotherapy.
Currently recommended RMP dosages in childhood tuberculosis lead to serum levels lower than those recommended for adults, probably due to different pharmacokinetics and pharmacodynamics in children. In children, it appears to be more valid to calculate RMP dosage on the basis of body surface area rather than body weight, leading to higher dosages especially in younger children.
利福平(RMP)是儿童抗结核治疗中的一种基本药物。世界卫生组织(WHO)目前的指南推荐口服剂量为每公斤体重10(8 - 12)毫克。
呈现一项研究,该研究调查单独口服RMP以及与乙胺丁醇(EMB)联合治疗后儿童体内的RMP血清水平。
在不同年龄组儿童单次口服10毫克/千克RMP以及与35毫克/千克EMB联合使用后,测定其RMP血清水平。
RMP血清水平低于接受相似口服剂量的成年人预期的水平。联合治疗时的RMP血清水平甚至低于单一疗法时的水平。
目前儿童结核病中推荐的RMP剂量导致血清水平低于成人推荐水平,这可能是由于儿童不同的药代动力学和药效学所致。在儿童中,基于体表面积而非体重来计算RMP剂量似乎更合理,这会导致更高的剂量,尤其是在幼儿中。